Cargando…

Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?

The management of intra-abdominal infections (IAIs) primarily includes adequate antimicrobial therapy and appropriate source control. Vancomycin is a fundamental and most effective antimicrobial agent. The aim of this study is to search and evaluate the quality of clinical evidences regarding the ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Song, Wang, Meng, Guan, Wenxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290861/
https://www.ncbi.nlm.nih.gov/pubmed/30584342
http://dx.doi.org/10.2147/IDR.S185331
_version_ 1783380168019017728
author Liu, Song
Wang, Meng
Guan, Wenxian
author_facet Liu, Song
Wang, Meng
Guan, Wenxian
author_sort Liu, Song
collection PubMed
description The management of intra-abdominal infections (IAIs) primarily includes adequate antimicrobial therapy and appropriate source control. Vancomycin is a fundamental and most effective antimicrobial agent. The aim of this study is to search and evaluate the quality of clinical evidences regarding the exclusive use of vancomycin for the management of adult IAIs. For this purpose, we first summarized the recommendations on exclusive use of vancomycin in adult IAIs from six leading guidelines and excavated the relevant supporting references. We subsequently conducted a literature search to screen eligible clinical studies in this field for possible systematic review. Our investigation demonstrates that the exclusive use of vancomycin is recommended in restricted indications, that is, IAIs caused by Enterococcus spp. or methicillin-resistant Staphylococcus aureus. However, the supporting references in the guidelines are more subjective instead of objective, which mainly originate from experts’ personal experiences or from the therapeutic efficacy of vancomycin in other types of infections rather than in IAIs. Furthermore, our literature search fails to find high-level evidence. In conclusion, current low-level evidences are inadequate to elicit strong recommendations on the exclusive use of vancomycin in the treatment of adult IAIs. Our study would be helpful for the rational use of vancomycin and deceleration of the emerging vancomycin resistance rates.
format Online
Article
Text
id pubmed-6290861
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62908612018-12-24 Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences? Liu, Song Wang, Meng Guan, Wenxian Infect Drug Resist Short Report The management of intra-abdominal infections (IAIs) primarily includes adequate antimicrobial therapy and appropriate source control. Vancomycin is a fundamental and most effective antimicrobial agent. The aim of this study is to search and evaluate the quality of clinical evidences regarding the exclusive use of vancomycin for the management of adult IAIs. For this purpose, we first summarized the recommendations on exclusive use of vancomycin in adult IAIs from six leading guidelines and excavated the relevant supporting references. We subsequently conducted a literature search to screen eligible clinical studies in this field for possible systematic review. Our investigation demonstrates that the exclusive use of vancomycin is recommended in restricted indications, that is, IAIs caused by Enterococcus spp. or methicillin-resistant Staphylococcus aureus. However, the supporting references in the guidelines are more subjective instead of objective, which mainly originate from experts’ personal experiences or from the therapeutic efficacy of vancomycin in other types of infections rather than in IAIs. Furthermore, our literature search fails to find high-level evidence. In conclusion, current low-level evidences are inadequate to elicit strong recommendations on the exclusive use of vancomycin in the treatment of adult IAIs. Our study would be helpful for the rational use of vancomycin and deceleration of the emerging vancomycin resistance rates. Dove Medical Press 2018-12-07 /pmc/articles/PMC6290861/ /pubmed/30584342 http://dx.doi.org/10.2147/IDR.S185331 Text en © 2018 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Short Report
Liu, Song
Wang, Meng
Guan, Wenxian
Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title_full Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title_fullStr Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title_full_unstemmed Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title_short Vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
title_sort vancomycin in the treatment of adult intra-abdominal infections: do we have strong evidences?
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290861/
https://www.ncbi.nlm.nih.gov/pubmed/30584342
http://dx.doi.org/10.2147/IDR.S185331
work_keys_str_mv AT liusong vancomycininthetreatmentofadultintraabdominalinfectionsdowehavestrongevidences
AT wangmeng vancomycininthetreatmentofadultintraabdominalinfectionsdowehavestrongevidences
AT guanwenxian vancomycininthetreatmentofadultintraabdominalinfectionsdowehavestrongevidences